Our Services
At Peptinovo Biopharma Inc., we are committed to transforming cancer treatment through innovative, targeted drug delivery solutions. Our services are built around our proprietary PALM™ (Peptide-Amphiphile Lipid Micelle) platform, enabling safer, more effective chemotherapy. We collaborate across the scientific and medical ecosystem to bring forward new, targeted therapies with reduced systemic toxicity.
1. Targeted Drug Delivery Platform: PALM™ Technology
Our flagship offering is the PALM™ drug delivery platform, a patented nanocarrier system that mimics the body’s natural high-density lipoproteins (HDLs) to deliver chemotherapy agents directly to cancer cells.
Core Features of PALM™:
Biomimetic Delivery:Utilizes synthetic HDL-like particles that exploit cholesterol uptake pathways—overexpressed in many tumors—for targeted delivery.
Drug Encapsulation:Formulates with a wide variety of hydrophobic chemotherapy drugs.
Controlled Release:Releases therapeutic agents precisely at the tumor site, maximizing impact on cancer cells while sparing healthy tissue.
Enhanced Solubility:Improves solubility and stability of hydrophobic chemotherapeutics.
Clinical Relevance:
Reduces off-target toxicity
Enhances drug efficacy by concentrating dosage at the tumor site
Enables repurposing and reengineering of existing chemotherapeutic agents with improved tolerability
2. Preclinical Drug Development Services
We specialize in the design, testing, and optimization of PALM™-based formulations using established chemotherapy agents. Our team leads a structured drug development process from conceptualization through IND-enabling studies.
Development Services Include:
Formulation Engineering:Creating stable micellar formulations for specific drug candidates
In Vitro Testing:Screening for cytotoxicity, cellular uptake, and tumor selectivity
In Vivo Animal Studies:Testing biodistribution, pharmacokinetics, and therapeutic efficacy
Toxicological Profiling:Conducting pre-GLP and GLP safety assessments for regulatory filings
3. Lead Product Development: PNB-281
We are advancing our lead candidate,PNB-281, a PALM™-formulated version of Paclitaxel, one of the most widely used chemotherapy agents.
Key Objectives of PNB-281:
Improve tolerability of Paclitaxel by reducing systemic exposure
Enhance anti-tumor activity through targeted drug accumulation
Reduce hypersensitivity reactions and need for toxic solvents (e.g., Cremophor EL)
PNB-281 is currently undergoing pre-IND enabling studies, with promising results in efficacy and safety compared to conventional formulations.
4. Multi-Drug Development Pipeline
In addition to PNB-281, we are actively developing PALM™-based formulations with other FDA-approved chemotherapeutic agents. These candidates are engineered to address limitations in solubility, safety, and tumor selectivity.
Pipeline Highlights:
Four additional drugs in preclinical development stages
Applications across various solid tumor indications
Designed for rapid progression through pre-IND and IND stages using 505(b)(2) regulatory pathways
5. Collaborative R&D Partnerships
We provide collaborative research and development services to pharmaceutical companies, academic institutions, and biotech innovators seeking to enhance drug delivery efficiency and safety.
Partnering Opportunities Include:
Custom Formulation Development:
Tailored PALM™ carriers for partner-selected drugs
Joint Preclinical Studies:
Shared design and execution of toxicology and efficacy studies
Licensing & Technology Transfer:
Access to PALM™ intellectual property for co-development
We offer deep technical expertise and flexible partnership models designed to accelerate innovation and improve therapeutic outcomes.
6. Oncology-Focused Scientific Expertise
Our multidisciplinary team brings decades of experience in oncology drug development, nanomedicine, and regulatory science. We offer end-to-end guidance on formulation science and early-stage oncology development.
Expertise Includes:
Drug delivery & nanocarrier technologies
Oncology biology and pharmacology
Regulatory strategy for pre-IND development
Scientific publications, data validation, and IP protection
Let’s Advance Cancer Therapy Together
Peptinovo is driven by science, guided by compassion, and committed to transforming cancer care. Our services are tailored to researchers, biotech partners, and clinical developers looking to improve the therapeutic index of chemotherapies through smarter delivery systems.
👉Contact Us to discuss your project, explore partnership opportunities, or learn how our PALM™ platform can optimize your oncology pipeline.
Enhancing Cancer Survival Rates Through the Development of Intelligent and Targeted Drug Delivery Technologies
Contact Us
Mail: [email protected]
Phone: (734) 306-3228
Peptinovo Biopharma Inc. 600 S Wagner Road Ann Arbor, Michigan 48103
Our Services
At Peptinovo Biopharma Inc., we are committed to transforming cancer treatment through innovative, targeted drug delivery solutions. Our services are built around our proprietary PALM™ (Peptide-Amphiphile Lipid Micelle) platform, enabling safer, more effective chemotherapy. We collaborate across the scientific and medical ecosystem to bring forward new, targeted therapies with reduced systemic toxicity.
1. Targeted Drug Delivery Platform: PALM™ Technology
Our flagship offering is the PALM™ drug delivery platform, a patented nanocarrier system that mimics the body’s natural high-density lipoproteins (HDLs) to deliver chemotherapy agents directly to cancer cells.
Core Features of PALM™:
Biomimetic Delivery:Utilizes synthetic HDL-like particles that exploit cholesterol uptake pathways—overexpressed in many tumors—for targeted delivery.
Drug Encapsulation:Formulates with a wide variety of hydrophobic chemotherapy drugs.
Controlled Release:Releases therapeutic agents precisely at the tumor site, maximizing impact on cancer cells while sparing healthy tissue.
Enhanced Solubility:Improves solubility and stability of hydrophobic chemotherapeutics.
Clinical Relevance:
Reduces off-target toxicity
Enhances drug efficacy by concentrating dosage at the tumor site
Enables repurposing and reengineering of existing chemotherapeutic agents with improved tolerability
2. Preclinical Drug Development Services
We specialize in the design, testing, and optimization of PALM™-based formulations using established chemotherapy agents. Our team leads a structured drug development process from conceptualization through IND-enabling studies.
Development Services Include:
Formulation Engineering:Creating stable micellar formulations for specific drug candidates
In Vitro Testing:Screening for cytotoxicity, cellular uptake, and tumor selectivity
In Vivo Animal Studies:Testing biodistribution, pharmacokinetics, and therapeutic efficacy
Toxicological Profiling:Conducting pre-GLP and GLP safety assessments for regulatory filings
3. Lead Product Development: PNB-281
We are advancing our lead candidate,PNB-281, a PALM™-formulated version of Paclitaxel, one of the most widely used chemotherapy agents.
Key Objectives of PNB-281:
Improve tolerability of Paclitaxel by reducing systemic exposure
Enhance anti-tumor activity through targeted drug accumulation
Reduce hypersensitivity reactions and need for toxic solvents (e.g., Cremophor EL)
PNB-281 is currently undergoing pre-IND enabling studies, with promising results in efficacy and safety compared to conventional formulations.
4. Multi-Drug Development Pipeline
In addition to PNB-281, we are actively developing PALM™-based formulations with other FDA-approved chemotherapeutic agents. These candidates are engineered to address limitations in solubility, safety, and tumor selectivity.
Pipeline Highlights:
Four additional drugs in preclinical development stages
Applications across various solid tumor indications
Designed for rapid progression through pre-IND and IND stages using 505(b)(2) regulatory pathways
5. Collaborative R&D Partnerships
We provide collaborative research and development services to pharmaceutical companies, academic institutions, and biotech innovators seeking to enhance drug delivery efficiency and safety.
Partnering Opportunities Include:
Custom Formulation Development:
Tailored PALM™ carriers for partner-selected drugs
Joint Preclinical Studies:
Shared design and execution of toxicology and efficacy studies
Licensing & Technology Transfer:
Access to PALM™ intellectual property for co-development
We offer deep technical expertise and flexible partnership models designed to accelerate innovation and improve therapeutic outcomes.
6. Oncology-Focused Scientific Expertise
Our multidisciplinary team brings decades of experience in oncology drug development, nanomedicine, and regulatory science. We offer end-to-end guidance on formulation science and early-stage oncology development.
Expertise Includes:
Drug delivery & nanocarrier technologies
Oncology biology and pharmacology
Regulatory strategy for pre-IND development
Scientific publications, data validation, and IP protection
Let’s Advance Cancer Therapy Together
Peptinovo is driven by science, guided by compassion, and committed to transforming cancer care. Our services are tailored to researchers, biotech partners, and clinical developers looking to improve the therapeutic index of chemotherapies through smarter delivery systems.
👉Contact Us to discuss your project, explore partnership opportunities, or learn how our PALM™ platform can optimize your oncology pipeline.
Enhancing Cancer Survival Rates Through the Development of Intelligent and Targeted Drug Delivery Technologies
Contact Us
Mail:[email protected]
Phone: (734) 306-3228
Peptinovo Biopharma Inc. 600 S Wagner Road Ann Arbor, Michigan 48103